July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Association of long-term RPE65 expression and photoreceptor preservation in RPE65-gene therapy-treated canines
Author Affiliations & Notes
  • Kristin Lee Gardiner
    Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
    Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • William A Beltran
    Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Gustavo D Aguirre
    Department of Clinical Sciences and Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Kristin Gardiner, None; William Beltran, None; Gustavo Aguirre, US Patent Application No. 11/511,201, (P)
  • Footnotes
    Support  EY-06855, -17549, the Foundation Fighting Blindness, the Van Sloun Fund for Canine Genetic Research, Hope for Vision, Stipend from the Vice Provost of Research (UPENN)
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5318. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kristin Lee Gardiner, William A Beltran, Gustavo D Aguirre; Association of long-term RPE65 expression and photoreceptor preservation in RPE65-gene therapy-treated canines. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5318. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal pigment epithelium-specific protein 65 kDa (RPE65) mutations result in deficiency of 11-cis-retinal, leading to multiple forms of retinal degeneration and early-onset blindness, including Leber congenital amaurosis (RPE65-LCA). Gene therapy trials in both canines and humans for RPE65-LCA have shown safety and efficacy, at least in the short term. We now have examined the association between photoreceptor (PR) structural preservation and RPE65 expression in treated areas in long-term studies of canine eyes.

Methods : The retinas of RPE65-/- dogs treated unilaterally by subretinal rAAV2-CBSB-hRPE65 were examined 4-5.5 years following treatment, and compared to untreated fellow eyes. All eyes were fixed in paraformaldehyde, posterior cups embedded in OCT media, and retinas serially sectioned. Histopathologic and immunohistochemical analysis of treated and untreated retinas was performed to characterize outer nuclear layer (ONL) thickness, outer segment (OS) and inner segment (IS) preservation, and RPE65 expression.

Results : H&E staining of serial sections extending from optic nerve to ora serrata indicated increased ONL thickness and improved IS and OS preservation in treated areas with RPE65 expression compared with corresponding regions in the untreated contralateral eyes, albeit still decreased compared to age-matched normal control eyes. The ONL thickness was focally preserved in areas up to 4000 µm from the nearest area of RPE65 labeling, indicating potential 11-cis-retinal diffusion from treated to untreated areas of the retina. The ONL thickness in these regions was less than in areas with RPE65 expression, and there appeared to be a general gradient of ONL thinning and loss of IS/OS preservation with increasing distance from treated areas having RPE65 expression.

Conclusions : Results suggest that RPE65 expression induced by subretinal gene therapy is sustained and may exert its protective effects on photoreceptors beyond the treated area. It is possible that retinoid diffusion in the interphotoreceptor matrix (IPM) away from the treatment site mediates this effect.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×